Leiden-based BIMINI Biotech secures funding to advance its innovative WASp modulator technology for treating aggressive blood cancers.
Leiden [NL]-based health tech startup BIMINI Biotech has secured a €3M seed funding round to accelerate the development of its groundbreaking treatments for haematological cancers. This milestone funding round, led by San Diego-based Torrey Pines Investment (TPI) with contributions from InnovationQuarter Capital (IQC), Libertatis Ergo Holding (LEH), and a business angel, will drive BIMINI’s mission to bring novel therapeutics to patients battling aggressive forms of leukaemia and lymphoma.
The company’s innovative approach addresses a critical need for effective therapies and treatments for aggressive blood cancers. Despite advancements, many patients relapse, facing limited options when standard treatments fail. BIMINI Biotech’s unique WASp modulator technology offers hope for a new wave of treatment possibilities, especially for elderly patients who cannot tolerate intensive therapies.
Paving the way for novel treatments for aggressive blood cancers
Founded in 2019, BIMINI Biotech is a preclinical-stage company dedicated to developing first-in-class small molecule therapeutics. These therapeutics target the Wiskott Aldrich Syndrome Protein (WASp), which plays a key role in cancer aggressiveness in haematological malignancies. By focusing on this innovative mode of action, the company aims to tackle unmet needs in lymphoma and leukaemia treatment.
Dr Digvijay Gahtory, CEO of BIMINI Biotech, shared the team’s excitement about this funding milestone: “We are excited to welcome this experienced group of investors and have the continued support of our existing shareholders that believe in the potential of our first-in-class WASp-modulators.”
The company has shown promising preclinical results, demonstrating the efficacy of WASp modulators in both in vitro and in vivo studies. These advancements mark a pivotal step toward filling the therapeutic gap in aggressive blood cancers.
A bold vision for aggressive blood cancer treatment
Rouslan Michtchenko, Director of Strategic Partnering and Investment at TPI, emphasised the significance of BIMINI’s work: “We are very pleased to support the team and exciting science behind BIMINI Biotech and see this European investment as another milestone of our strategic expansion in such high-impact research areas as haematology.”
The funding will also enable BIMINI to leverage advanced tools like Expert Systems’ hybrid AI platform for drug design, expediting preclinical safety and efficacy validation. This collaboration aims to ensure the company’s WASp modulators reach clinical trials, bringing hope to patients with high-relapse cancers.
Dr Maurits van den Nieuwboer, COO of BIMINI Biotech, highlighted the urgency of their mission: “For aggressive leukaemia and lymphoma subtypes, it is not a matter ‘if’ patients relapse, but ‘when’ patients relapse. As such, there is still a dire need for novel therapeutic strategies. BIMINI Biotech can fill this gap. With this new investment round, we can really progress the development of our portfolio.”
Forging a path to a brighter future
The investment comes as BIMINI Biotech positions itself at the forefront of cancer treatment innovation. Linn Bäckegren-van Ingen, Investment Manager at IQC, praised the team’s dedication: “We are impressed by the dedication and expertise of the BIMINI team and look forward to seeing them take the next steps in this important journey. Therefore, we are excited to support BIMINI Biotech in their mission to improve outcomes for leukaemia and lymphoma patients.”
As BIMINI Biotech accelerates its preclinical development, its innovative therapies offer renewed hope to patients worldwide, marking a transformative step in the fight against aggressive blood cancers.
The post Aggressive blood cancers face new resistance as BIMINI Biotech lands €3M appeared first on Tech Funding News.